Showing results (251-260 of 297) with videos related to
Sort By:
Pageof 30
Journal of the American Society of Nephrology : JASN|March 29, 2026
Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover TrialHiddo J L Heerspink, Irene L Noronha, Jose Luis Górriz, et al.BMJ Open|October 6, 2021
A pilot randomised controlled trial of a structured, home-based exercise programme on cardiovascular structure and function in kidney transplant recipients: the ECSERT study design and methodsRoseanne E Billany, Noemi Vadaszy, Nicolette C Bishop, et al.Journal of the American Society of Nephrology : JASN|September 11, 2016
A Multicenter Study of the Predictive Value of Crescents in IgA NephropathyMark Haas, Jacobien C Verhave, Zhi-Hong Liu, et al.Journal of Medical Internet Research|November 14, 2022
The Codevelopment of "My Kidneys & Me": A Digital Self-management Program for People With Chronic Kidney DiseaseCourtney J Lightfoot, Thomas J Wilkinson, Michelle Hadjiconstantinou, et al.Wellcome Open Research|October 23, 2018
Protocol and rationale for the first South Asian 5-year prospective longitudinal observational cohort study and biomarker evaluation investigating the clinical course and risk profile of IgA nephropathy: GRACE IgANI cohortSuceena Alexander, George T John, Anila Korula, et al.Journal of Medicinal Chemistry|April 19, 2021
Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)Michael G Hahn, Thomas Lampe, Sherif El Sheikh, et al.The New England Journal of Medicine|November 6, 2025
A Phase 3 Trial of Atacicept in Patients with IgA NephropathyRichard Lafayette, Sean J Barbour, Robert M Brenner, et al.Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Individualized treatment effects of corticosteroids in IgA nephropathyDavid L Hoelscher, Nikolas Ej Schmitz, Leon Niggemeier, et al.Science Translational Medicine|July 1, 2016
Low α-defensin gene copy number increases the risk for IgA nephropathy and renal dysfunctionZhen Ai, Ming Li, Wenting Liu, et al.Lancet (London, England)|June 4, 2026
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trialHiddo J L Heerspink, Meg J Jardine, Donald E Kohan, et al.Pageof 30